Jason Haas - 12 Aug 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Reporting relationship: Director
Issuer ticker: LGND
Reported as of: 12 Aug 2026
Net transaction value: -$2,090,062
SEC form: 4
Accepted by SEC: 14 Aug 2026, 17:04:53 UTC
Prior SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Jason Haas

Key filing fact

Jason Haas filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 14 Aug 2026.

Key facts

This page summarizes Jason Haas's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Aug 2026, 17:04.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: -$2,090,062.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001883821 Primary reporting owner

Haas Jason

Relationship: Director
Address: 555 HERITAGE DRIVE, SUITE 200, JUPITER
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Jason Haas
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LGND transaction

Common Stock

Options Exercise

Transaction value
Shares: +6,138
Change %: +123%
Price: $51.56^*
Shares after: 11,119
Date: 12 Aug 2026
Ownership: Direct

LGND transaction

Common Stock

Sale

Transaction value: $2,090,062
Shares: -7,138
Change %: -64%
Price: $292.81
Shares after: 3,981
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LGND transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -6,138
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,138
Exercise price: $51.56
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.